Long Position on NUVA @ $32.75 on 11/26/2013 (Momentum)

NuVasive (NUVA) is a medical device company.

The firm engages in the design, development, and marketing of minimally disruptive surgical products and procedurally integrated solutions for the spine.

The company’s products focus on applications for spine fusion surgery. It offers products for the thoracolumbar spine and the cervical spine primarily used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s principal products include a minimally disruptive surgical platform called Maximum Access Surgery (MAS), as well as cervical, biologics, and motion preservation products. Its MAS platform combines three categories of product offerings, including NVM5 and NVJJB, its proprietary software-driven nerve detection and avoidance systems, and intra-operative monitoring support services for insight into the nervous system during spine and other surgeries; MaXcess, an integrated split-blade retractor system; and various specialized implants.

The company’s biologic products include allograft, a donated human tissue; FormaGraft, a collagen synthetic product; Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells; and AttraX, a synthetic bone graft material. It also offers solutions for cervical fusion surgery, including allograft and CoRoent implants, as well as cervical plating and posterior fixation products. In addition, the company’s products comprise PCM device, a motion preserving total disc replacement device; and XL TDR, a mechanical total disc replacement solution.

NuVasive, Inc. sells its products through directly-employed sales shareowners, independent sales agents, and distributors to surgeons and hospitals in the United States and internationally.

Shares have formed a bullish "flag" following the company's better than expected earnings report. Higher share prices are expected for this stock.

52-Week Trading Range: $13.69 - $33.89

Entry Point: $32.75

Stop Loss: $31.10

Target Price: $36.02

Updates

12/26/2013 9:47:37 AM

NUVA failed to reach our target price in 30 days or less. We are closing the position.

Position closed on 12/26/2013 at price of $32.86 with a 0.34% gain in 30 days.

Back to Portfolio